The drug eluting balloons catheters market size has grown rapidly in recent years. It will grow from $1.65 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, growing adoption of percutaneous coronary interventions, advancements in balloon catheter materials, clinical acceptance of paclitaxel-coated devices, expansion of interventional cardiology centers.
The drug eluting balloons catheters market size is expected to see rapid growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing demand for minimally invasive vascular therapies, rising adoption of sirolimus-based balloons, expansion of peripheral vascular disease treatments, growing investments in next-generation catheter technologies, increasing focus on long-term patient outcomes. Major trends in the forecast period include increasing adoption of drug-coated balloon technologies, rising use in coronary and peripheral interventions, growing preference for stent-free treatment options, expansion of advanced drug coating techniques, enhanced focus on restenosis prevention.
The increasing prevalence of peripheral and cardiovascular diseases is expected to drive the growth of the drug-eluting balloon catheter market in the coming years. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) specifically involves the narrowing of arteries that reduces blood flow, primarily to the arms or legs. Drug-eluting balloon catheters are used in the treatment of coronary artery disease (CAD) and consist of semi-compliant angioplasty balloons coated with anti-proliferative agents that, upon contact with the vessel wall, exert anti-restenotic effects. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted cardiovascular disease mortality rate increased to 233.3 deaths per 100,000 in 2024, representing a 4% year-on-year rise from 224.4 deaths per 100,000 in 2023. Consequently, the growing prevalence of peripheral and cardiovascular diseases is contributing to the expansion of the drug-eluting balloon catheter market.
Key players in the drug-eluting balloon catheter market are intensifying their efforts to develop next-generation products with advanced technologies to secure a competitive advantage. For instance, in March 2024, Boston Scientific Corporation, a U.S.-based biomedical and biotechnology engineering firm, announced it had received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). This product is the first drug-coated coronary balloon available in the U.S. specifically designed for treating in-stent restenosis (ISR), a condition where plaque or scar tissue obstructs a previously stented vessel. The AGENT DCB features a paclitaxel coating that provides a therapeutic dose to the vessel wall, effectively reducing ISR recurrence without the need for additional stents or radiation. Clinical trials demonstrated a 49% reduction in the risk of heart attack at the target site, along with low rates of adverse events.
In June 2023, Translumina Therapeutics Company acquired Blue Medical Devices BV for an undisclosed amount. This strategic acquisition aimed to integrate Blue Medical's unique drug application technology into Translumina's product lines, expanding offerings in neurovascular and peripheral interventions and enhancing drug coating capabilities. Blue Medical Devices BV is a Netherlands-based medical device company specializing in producing drug-eluting balloon catheters.
Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB.
North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug eluting balloons catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the drug eluting balloon catheters market by increasing costs of imported pharmaceutical coatings, catheter polymers, precision tubing, and manufacturing equipment used in coronary and peripheral devices. Hospitals and catheterization laboratories in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing device pricing and procurement complexity. However, they are also encouraging localized catheter manufacturing, regional sourcing of raw materials, and investment in domestic production capabilities.
The drug eluting balloons catheters market research report is one of a series of new reports that provides drug eluting balloons catheters market statistics, including drug eluting balloons catheters industry global market size, regional shares, competitors with a drug eluting balloons catheters market share, detailed drug eluting balloons catheters market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting balloons catheters industry. This drug eluting balloons catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A drug-eluting balloon catheter is a medical device utilized in the treatment of coronary artery disease through percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon that is coated with an anti-proliferative drug. During inflation, the drug is released into the vessel wall, aiming to prevent restenosis and reduce the risk of late thrombosis without the need for implanting a permanent foreign object.
The main types of drug-eluting balloon catheters include those designed for coronary artery disease and peripheral vascular disease. Coronary artery disease drug-eluting balloon catheters deliver antiproliferative drugs directly to the vessel wall using a lipophilic matrix, eliminating the need for a permanent structure such as a metal prosthesis or persistent polymer. Various drugs such as paclitaxel and sirolimus are used, and the catheters are made from raw materials such as nylon, polyurethane, and others. They find applications in hospitals, clinics, ambulatory surgical centers, and catheterization laboratories.
The drug-eluting balloon catheter market consists of sales of everolimus and stellarex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug eluting balloons catheters market size is expected to see rapid growth in the next few years. It will grow to $2.92 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing demand for minimally invasive vascular therapies, rising adoption of sirolimus-based balloons, expansion of peripheral vascular disease treatments, growing investments in next-generation catheter technologies, increasing focus on long-term patient outcomes. Major trends in the forecast period include increasing adoption of drug-coated balloon technologies, rising use in coronary and peripheral interventions, growing preference for stent-free treatment options, expansion of advanced drug coating techniques, enhanced focus on restenosis prevention.
The increasing prevalence of peripheral and cardiovascular diseases is expected to drive the growth of the drug-eluting balloon catheter market in the coming years. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) specifically involves the narrowing of arteries that reduces blood flow, primarily to the arms or legs. Drug-eluting balloon catheters are used in the treatment of coronary artery disease (CAD) and consist of semi-compliant angioplasty balloons coated with anti-proliferative agents that, upon contact with the vessel wall, exert anti-restenotic effects. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted cardiovascular disease mortality rate increased to 233.3 deaths per 100,000 in 2024, representing a 4% year-on-year rise from 224.4 deaths per 100,000 in 2023. Consequently, the growing prevalence of peripheral and cardiovascular diseases is contributing to the expansion of the drug-eluting balloon catheter market.
Key players in the drug-eluting balloon catheter market are intensifying their efforts to develop next-generation products with advanced technologies to secure a competitive advantage. For instance, in March 2024, Boston Scientific Corporation, a U.S.-based biomedical and biotechnology engineering firm, announced it had received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). This product is the first drug-coated coronary balloon available in the U.S. specifically designed for treating in-stent restenosis (ISR), a condition where plaque or scar tissue obstructs a previously stented vessel. The AGENT DCB features a paclitaxel coating that provides a therapeutic dose to the vessel wall, effectively reducing ISR recurrence without the need for additional stents or radiation. Clinical trials demonstrated a 49% reduction in the risk of heart attack at the target site, along with low rates of adverse events.
In June 2023, Translumina Therapeutics Company acquired Blue Medical Devices BV for an undisclosed amount. This strategic acquisition aimed to integrate Blue Medical's unique drug application technology into Translumina's product lines, expanding offerings in neurovascular and peripheral interventions and enhancing drug coating capabilities. Blue Medical Devices BV is a Netherlands-based medical device company specializing in producing drug-eluting balloon catheters.
Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB.
North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug eluting balloons catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the drug eluting balloon catheters market by increasing costs of imported pharmaceutical coatings, catheter polymers, precision tubing, and manufacturing equipment used in coronary and peripheral devices. Hospitals and catheterization laboratories in North America and Europe are most affected due to reliance on imported raw materials, while Asia-Pacific faces cost pressure on device exports. These tariffs are increasing device pricing and procurement complexity. However, they are also encouraging localized catheter manufacturing, regional sourcing of raw materials, and investment in domestic production capabilities.
The drug eluting balloons catheters market research report is one of a series of new reports that provides drug eluting balloons catheters market statistics, including drug eluting balloons catheters industry global market size, regional shares, competitors with a drug eluting balloons catheters market share, detailed drug eluting balloons catheters market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting balloons catheters industry. This drug eluting balloons catheters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A drug-eluting balloon catheter is a medical device utilized in the treatment of coronary artery disease through percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon that is coated with an anti-proliferative drug. During inflation, the drug is released into the vessel wall, aiming to prevent restenosis and reduce the risk of late thrombosis without the need for implanting a permanent foreign object.
The main types of drug-eluting balloon catheters include those designed for coronary artery disease and peripheral vascular disease. Coronary artery disease drug-eluting balloon catheters deliver antiproliferative drugs directly to the vessel wall using a lipophilic matrix, eliminating the need for a permanent structure such as a metal prosthesis or persistent polymer. Various drugs such as paclitaxel and sirolimus are used, and the catheters are made from raw materials such as nylon, polyurethane, and others. They find applications in hospitals, clinics, ambulatory surgical centers, and catheterization laboratories.
The drug-eluting balloon catheter market consists of sales of everolimus and stellarex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug Eluting Balloons Catheters Market Characteristics
3. Drug Eluting Balloons Catheters Market Supply Chain Analysis
4. Global Drug Eluting Balloons Catheters Market Trends and Strategies
5. Drug Eluting Balloons Catheters Market Analysis of End Use Industries
7. Global Drug Eluting Balloons Catheters Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug Eluting Balloons Catheters Total Addressable Market (TAM) Analysis for the Market
9. Drug Eluting Balloons Catheters Market Segmentation
10. Drug Eluting Balloons Catheters Market Regional and Country Analysis
11. Asia-Pacific Drug Eluting Balloons Catheters Market
12. China Drug Eluting Balloons Catheters Market
13. India Drug Eluting Balloons Catheters Market
14. Japan Drug Eluting Balloons Catheters Market
15. Australia Drug Eluting Balloons Catheters Market
16. Indonesia Drug Eluting Balloons Catheters Market
17. South Korea Drug Eluting Balloons Catheters Market
18. Taiwan Drug Eluting Balloons Catheters Market
19. South East Asia Drug Eluting Balloons Catheters Market
20. Western Europe Drug Eluting Balloons Catheters Market
21. UK Drug Eluting Balloons Catheters Market
22. Germany Drug Eluting Balloons Catheters Market
23. France Drug Eluting Balloons Catheters Market
24. Italy Drug Eluting Balloons Catheters Market
25. Spain Drug Eluting Balloons Catheters Market
26. Eastern Europe Drug Eluting Balloons Catheters Market
27. Russia Drug Eluting Balloons Catheters Market
28. North America Drug Eluting Balloons Catheters Market
29. USA Drug Eluting Balloons Catheters Market
30. Canada Drug Eluting Balloons Catheters Market
31. South America Drug Eluting Balloons Catheters Market
32. Brazil Drug Eluting Balloons Catheters Market
33. Middle East Drug Eluting Balloons Catheters Market
34. Africa Drug Eluting Balloons Catheters Market
36. Drug Eluting Balloons Catheters Market Competitive Landscape and Company Profiles
37. Drug Eluting Balloons Catheters Market Other Major and Innovative Companies
40. Drug Eluting Balloons Catheters Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Drug Eluting Balloons Catheters Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug eluting balloons catheters market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug eluting balloons catheters? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting balloons catheters market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Coronary Artery Disease; Peripheral Vascular Disease; Drug-Eluting Balloon Catheters2) By Drug: Paclitaxel; Sirolimus; Other Drugs
3) By Raw Material: Nylon; Polyurethane; Other Raw Materials
4) By End-User: Hospitals And Clinics; Ambulatory Surgical Centers; Catheterization Laboratories
Subsegments:
1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters; Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters; Coronary Small-Vessel Drug-Eluting Balloon Catheters2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters; Femoro-Popliteal Drug-Eluting Balloon Catheters; Below-the-Knee (BTK) Drug-Eluting Balloon Catheters
3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters
Companies Mentioned: Abbott Laboratories; Medtronic PLC; Boston Scientific Corporation; B Braun Melsungen Aktiengesellschaft; Terumo Corporation; Cook Medical LLC; Lepu Medical Technology Co. Ltd.; Meril Life Sciences Pvt. Ltd.; MicroPort Scientific Corporation; BIOTRONIK SE & Co. KG; Acotec Scientific Co. Ltd.; Cordis Corporation; Biosensors International Group Ltd.; Zylox-Tonbridge Medical Technology Co. Ltd.; Hexacath Limited; Zhejiang Barty Medical Technology Co. Ltd.; Cardionovum GmbH; Nano Therapeutics Pvt. Ltd.; Tokai Medical Products Inc.; Opto Circuits Limited; Acrostak (Schweiz) AG; Concept Medical Inc.; Aachen Resonance GmbH; AR Baltic Medical UAB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug Eluting Balloons Catheters market report include:- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- B Braun Melsungen Aktiengesellschaft
- Terumo Corporation
- Cook Medical LLC
- Lepu Medical Technology Co. Ltd.
- Meril Life Sciences Pvt. Ltd.
- MicroPort Scientific Corporation
- BIOTRONIK SE & Co. KG
- Acotec Scientific Co. Ltd.
- Cordis Corporation
- Biosensors International Group Ltd.
- Zylox-Tonbridge Medical Technology Co. Ltd.
- Hexacath Limited
- Zhejiang Barty Medical Technology Co. Ltd.
- Cardionovum GmbH
- Nano Therapeutics Pvt. Ltd.
- Tokai Medical Products Inc.
- Opto Circuits Limited
- Acrostak (Schweiz) AG
- Concept Medical Inc.
- Aachen Resonance GmbH
- AR Baltic Medical UAB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.86 Billion |
| Forecasted Market Value ( USD | $ 2.92 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
